Brought to you by 
Tzamal gets rights to sell Cardiome's Brinavess in Israel
25 Sep 2013
Executive Summary
Cardiome Pharma Corp. (cardiovascular therapeutics) has granted Tzamal Medical Ltd. (provides pharmaceuticals and medical devices in Israel) exclusive Israeli marketing and distribution rights to Brinavess (vernakalant). The deal is for an initial three-year term and is renewable each year thereafter.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Tzamal gets rights to sell Cardiome's Brinavess in Israel
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice